Arch Biopartners Inc. ARCH.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 33.98% | -67.32% | |||
| Gross Profit | -33.98% | 67.32% | |||
| SG&A Expenses | -16.45% | -73.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.49% | -71.59% | |||
| Operating Income | -3.49% | 71.59% | |||
| Income Before Tax | 9.61% | 66.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.61% | 66.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.61% | 66.04% | |||
| EBIT | -3.49% | 71.59% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 10.53% | 66.27% | |||
| Normalized Basic EPS | 8.57% | 66.98% | |||
| EPS Diluted | 10.53% | 66.27% | |||
| Normalized Diluted EPS | 8.57% | 66.98% | |||
| Average Basic Shares Outstanding | 1.48% | 1.26% | |||
| Average Diluted Shares Outstanding | 1.48% | 1.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||